Characteristic | Group; mean (SD) [and range] | P value* | ||
---|---|---|---|---|
Good responders n = 34 | Poor responders n = 34 | Control subjects n = 76 | ||
Sex, M/F | 9/25 | 6/28 | 21/55 | 0.29 |
Age, y | 38.6 (7.5) [26–50] | 37.3 (9.1) [19–51] | 38.2 (10.9) [19–60] | 0.86 |
Age of onset, y | 23.1 (7.4) [15–49] | 21.6 (6.6) [13–47] | NA | 0.35 |
Illness duration, y | 15.8 (7.8) [1–29] | 16.0 (6.8) [1–29] | NA | 0.88 |
CPZE, mg | 580 (340) | 697 (431) | NA | 0.22 |
BPRS total score | 38.1 (8.0) | 44.1 (12.3) | NA | 0.02 |
GAF score | 48.4 (6.6) | 31.2 (6.2) | NA | < 0.001 |
BPRS = Brief Psychiatric Rating Scale19; CPZE = chlorpromazine equivalent; F = female; GAF = Global Assessment of Functioning18; M =male; NA = not applicable; SD = standard deviation.
↵* Categorical data were analyzed with χ2 test, continuous data with 1-way analysis of variance or t test.